New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM 87106, USA.
Expert Opin Biol Ther. 2013 Feb;13(2):183-96. doi: 10.1517/14712598.2012.740006. Epub 2012 Dec 19.
Osteoporosis is a systemic skeletal disorder that weakens bones and increases the risk of fractures. It is caused by perturbations of bone remodeling, the coupled process whereby bone is continually resorbed and formed in small discrete units. Despite the availability of cost-effective pharmacological agents that reduce fracture risk, many patients who could benefit from treatment are not receiving it. Advances in the understanding of the molecular regulators of bone remodeling have led to the identification of new targets for therapeutic intervention. Monoclonal antibodies directed to these targets have recently been developed, providing new ways of modulating bone remodeling that may provide additional benefits beyond previously available therapy.
An approved fully human monoclonal antibody to receptor activator of nuclear factor-κB ligand, the principal regulator of osteoclastic bone resorption, reduces the risk of fractures in postmenopausal women with osteoporosis. Monoclonal antibodies in development include inhibitors of sclerostin and Dickhopf1, with osteoanabolic activity that may be beneficial in the treatment of osteoporosis.
Monoclonal antibodies to molecular regulators of bone remodeling represent a new class of compounds for the management of osteoporosis and other skeletal disorders associated with an imbalance of bone resorption and formation.
骨质疏松症是一种全身性骨骼疾病，会削弱骨骼并增加骨折的风险。它是由骨重建的紊乱引起的，骨重建是一个耦合过程，即骨骼在小的离散单元中不断被吸收和形成。尽管有经济有效的药物可降低骨折风险，但许多可以从中受益的患者并未接受治疗。对骨重建分子调节剂的理解的进步，导致了治疗干预的新靶点的确定。最近开发了针对这些靶点的单克隆抗体，为调节骨重建提供了新的方法，可能提供以前可用的治疗方法之外的额外益处。
一种已获批的针对核因子-κB 配体受体激活剂的全人源单克隆抗体，是破骨细胞骨吸收的主要调节剂，可降低绝经后骨质疏松症妇女的骨折风险。正在开发中的单克隆抗体包括硬化素和 Dickhopf1 的抑制剂，它们具有成骨活性，可能有益于骨质疏松症的治疗。
骨重建分子调节剂的单克隆抗体代表了一类用于治疗骨质疏松症和其他与骨吸收和形成失衡相关的骨骼疾病的新型化合物。
